Kevin Chen Resigns as Head of Cardiovascular Business at Johnson & Johnson China, Pursues New External Opportunities

Aug 27, 2024 17:30 CST Updated 17:30

Johnson & Johnson

Medical Device R&D and Manufacturer

Recently, Johnson & Johnson China officially announced internally that Kevin Chen (Chu-Hui Chen), General Manager of the Cardiovascular and Specialty Solutions Division of Johnson & Johnson Medical Technology China, as well as the Head of External Affairs and Market Access, has submitted his resignation to pursue external development opportunities. His last working day at Johnson & Johnson will be September 16, 2024.

During the transition period, Edward Zhou will act as the interim manager for the CSS Division, External Affairs, and Market Access departments.

Kevin joined Johnson & Johnson in 2009, holding management positions in the Ethicon ASP Division, the Endo Division's Harmonic business, as well as the Gynecare and Mentor divisions. After returning to Johnson & Johnson in 2015, Kevin also took on important leadership roles such as Head of Channel Management, Strategic Customers, Operations, and Professional Education.

Johnson & Johnson stated that during his 14-year tenure, Kevin has held leadership positions in various business and functional departments. Guided by the Credo, he has earned respect and trust through his excellent leadership, professional expertise, and focus on talent development.

On March 31, 2023, Chen Xi, the former General Manager of Johnson & Johnson Medical Technology China's Cardiovascular and Professional Solutions Division, resigned. Kevin then took over the position.

Johnson & Johnson stated that since Kevin became the General Manager of the Cardiovascular and Specialty Solutions (CSS) division, he has led the team to uphold a steadfast commitment to patients and customers. He continuously explores business growth opportunities and models, promotes digital innovation, and further strengthens and enhances the competitiveness and cohesion of the team. Currently, CSS China has become an important growth engine for the company’s business in the Asia-Pacific region and globally.

Johnson & Johnson's cardiovascular business has seen rapid growth in recent years, primarily driven by its electrophysiology segment; in the first half of 2024, its global electrophysiology revenue reached $2.667 billion, a year-on-year increase of 16.5%.

Moreover, Johnson & Johnson also stated that, over the past two years, Kevin has concurrently served as Vice President of External Affairs and Market Access, working closely with various business and functional departments. He has continuously improved the external affairs and end-to-end market access strategy implementation and execution for Johnson & Johnson Medical (China) Ltd., successfully completing volume-based procurement for several key products and promoting high-quality medical products to serve more patients.

Source: MedTalent Medical Talent

Business Cooperation

130 6172 3098

zakk.cui@siqibest.com

ClickRead the Original Text Learn More